Menicon (7780) FY2027 Q1 Earnings Report

Quick View

Executive Summary

In addition to revenue growth, an improved gross margin and restrained SG&A expenses combined to generate earnings growth substantially exceeding revenue growth, reflecting operating leverage. Revenue was ¥323.8B (+7.0% YoY), Operating Income was ¥34.3B (+74.9%), Ordinary Income was ¥33.6B (+90.1%), and Net Income was ¥22.3B (+124.9%). Growth in revenue and improved profitability in the core Vision Care Business, which accounted for 93.3% of total revenue, led consolidated growth.

Factors Affecting Performance

【Revenue】Revenue increased 7.0% YoY to ¥323.8B. The core Vision Care Business generated ¥302.1B (+7.1%) and accounted for 93.3% of consolidated revenue, leading growth. Other businesses, including Healthcare and Lifecare, also recorded revenue growth of 6.4% to ¥21.6B.

【Profit and Loss】Operating Income increased 74.9% YoY to ¥34.3B, Ordinary Income increased 90.1% to ¥33.6B, and Net Income increased 124.9% to ¥22.3B, representing earnings growth substantially exceeding the rate of revenue growth. The gross margin improved to 54.3% from 53.2% in the previous year, an improvement of approximately 1.1pt, while SG&A expenses were contained at ¥141.4B, nearly unchanged from the previous year. The SG&A ratio declined to 43.7% from 46.8%, an improvement of approximately 3.1pt. The Vision Care Business segment profit margin improved to 17.2% from 12.9% in the previous year, while the segment loss in Other Businesses expanded to ¥1.5B from ¥1.0B in the previous year. Corporate expenses were ¥16.1B, up 2.5% YoY and below the rate of revenue growth, contributing to improved consolidated margins. Extraordinary gains and losses were minor, and non-operating income and expenses were limited; consequently, the difference between Profit Before Tax and Operating Income was small. In conclusion, this was a high-quality earnings result characterized by revenue and earnings growth, with the earnings growth rate substantially exceeding the revenue growth rate.

Segment Analysis

The Vision Care Business is the core business driving consolidated performance, with revenue of ¥302.1B (+7.1% YoY), segment profit of ¥51.9B (+42.7%), and a profit margin of 17.2% (12.9% in the previous year). Other Businesses, including Healthcare and Lifecare, recorded revenue of ¥21.6B (+6.4%) and a segment loss of ¥1.5B (¥1.0B in the previous year), indicating an expanded loss despite revenue growth. Corporate expenses were ¥16.1B (+2.5% YoY), remaining nearly flat and not materially eroding the earnings contribution from the Vision Care Business.

Key Financial Indicators

【Profitability】The Operating Income margin improved to 10.6% from 6.5% in the same period of the previous year, an improvement of approximately 4.1pt. The Net Income margin also improved to 6.9% from 3.3% in the previous year, an improvement of approximately 3.6pt. Annualized ROE was 9.3%. 【Cash Quality】The difference between Operating Income of ¥34.3B and Profit Before Tax of ¥33.6B was limited to ¥0.7B, indicating that earnings were primarily generated by the core business, with limited reliance on extraordinary gains and losses or non-operating income. Meanwhile, inventories of ¥209.8B and accounts receivable of ¥167.4B increased 13.2% YoY, exceeding the pace of revenue growth, potentially affecting the conversion of earnings into cash through the accumulation of funds in inventory and accounts receivable. 【Investment Efficiency】Total asset turnover was approximately 0.637x. Construction in progress of ¥194.9B accounted for 19.8% of property, plant and equipment, and the progress of commissioning and monetizing investment projects will influence capital efficiency going forward. 【Financial Soundness】The Equity Ratio was high at 47.3%, while the current ratio was 231.6%, indicating sound short-term financial safety. Although short-term borrowings increased substantially to ¥65.6B from ¥18.7B in the previous year, cash and deposits remained substantial at ¥340.7B, ensuring sufficient repayment capacity.

Cash Flow Analysis

Because detailed disclosure of the statement of cash flows was not included in these results, funding trends are analyzed based on changes in the balance sheet. Cash and deposits increased to ¥340.7B from ¥326.1B in the previous year, indicating that the funding base has been maintained. Meanwhile, inventories of ¥209.8B and accounts receivable of ¥167.4B increased YoY. In particular, the 13.2% increase in accounts receivable exceeded the 7.0% revenue growth rate, suggesting that funds may be tied up in inventory and accounts receivable. Accounts payable were ¥59.8B, up only 3.9% YoY, indicating a limited funding benefit from trade payables. Short-term borrowings increased substantially to ¥65.6B from ¥18.7B in the previous year, indicating greater reliance on short-term financing. Construction in progress increased to ¥194.9B, suggesting that funding needs associated with capital expenditures remain ongoing. Overall, although earnings are steadily expanding, the impact of growth in working capital on funding efficiency requires continued monitoring.

Quality of Earnings

The difference between Operating Income of ¥34.3B and Profit Before Tax of ¥33.6B was limited to ¥0.7B, indicating that earnings were primarily generated by the core business. Non-operating income was ¥1.7B, equivalent to approximately 0.5% of revenue, and consisted mainly of small amounts such as foreign exchange gains of ¥0.6B, dividends received of ¥0.2B, and interest income of ¥0.2B; these were not significant drivers of earnings growth. Non-operating expenses were ¥2.4B, of which interest expenses accounted for ¥2.2B. Extraordinary gains and losses were minor, consisting of an extraordinary gain of ¥0.02B and an extraordinary loss of ¥0.04B, indicating that temporary factors did not materially distort Net Income. Comprehensive Income was ¥31.8B, and the difference of ¥9.5B from Net Income of ¥22.3B was primarily attributable to foreign currency translation adjustments of ¥8.2B, reflecting the positive impact of foreign exchange fluctuations related to overseas businesses on comprehensive income. Meanwhile, the fact that accounts receivable and inventories increased at a pace exceeding revenue growth suggests that a certain gap may have emerged between accounting earnings and the actual speed of cash collection.

Earnings Forecast and Guidance

The full-year company forecasts are revenue of ¥1330.0B (+5.9% YoY), Operating Income of ¥110.0B (+7.5%), and Ordinary Income of ¥105.0B (-4.7%). The Q1 progress rates were 24.3% for revenue, 31.2% for Operating Income, and 34.3% for Net Income (actual results of ¥22.3B against the forecast of ¥65.0B), all exceeding the pace of revenue progress. There were no revisions to the earnings forecast or dividend forecast for the quarter. Against the full-year Operating Income growth forecast of 7.5%, Q1 earnings growth was 74.9%, suggesting that the company’s plan may incorporate profit-margin normalization and additional costs toward the second half of the fiscal year.

Shareholder Returns

The full-year dividend forecast is ¥28.00 per share, with no revision to the dividend forecast as of the end of the quarter. Based on the weighted-average number of shares outstanding during the period of 74,225,971 shares, the forecast total dividend amount is approximately ¥20.8B, resulting in a Payout Ratio of approximately 32.0% against the full-year Net Income forecast of ¥65.0B. The financial base, consisting of net assets of ¥962.5B and cash and deposits of ¥340.7B, is sufficient to support the payment of the forecast dividend.

Risk Factors

1. Concentration Risk in the Core Business: The Vision Care Business accounts for 93.3% of consolidated revenue, creating a structure in which changes in demand trends and the competitive environment in this business could have a significant impact on overall consolidated performance.

2. Working Capital Efficiency: Inventories of ¥209.8B and accounts receivable of ¥167.4B increased 13.2% YoY, exceeding the 7.0% revenue growth rate. The accumulation of funds in inventory and accounts receivable could affect the speed at which earnings are converted into cash.

3. Expansion of Losses in Other Businesses: Other Businesses recorded a segment loss of ¥1.5B against revenue of ¥21.6B, with the loss expanding from ¥1.0B in the previous year. In addition, short-term borrowings increased to ¥65.6B from ¥18.7B in the previous year, requiring attention to the increased reliance on short-term financing.

Industry Benchmark (For Reference; Based on Our Analysis)

Industry Benchmark (manufacturing)

Profitability and Returns

The Operating Income margin exceeds the industry median, while the Net Income margin is broadly in line with the industry median.

Growth and Capital Efficiency

The revenue growth rate is slightly above the industry median.

※Source: Based on our analysis

Key Takeaways from the Earnings Results

1. In Q1, revenue increased 7.0%, while Operating Income rose 74.9%, achieving earnings growth substantially exceeding revenue growth. The operating leverage effect from the improved gross margin and nearly flat SG&A expenses was clearly evident.

2. Progress against the full-year forecast was 24.3% for revenue, compared with 31.2% for Operating Income and 34.3% for Net Income, indicating that profit metrics are progressing ahead. Improved profitability in the core Vision Care Business (17.2%, compared with 12.9% in the previous year) drove consolidated profitability.

3. The pace of increase in inventories and accounts receivable exceeded revenue growth, making working capital trends a key point for monitoring funding efficiency alongside earnings growth.

Theoretical Share Price (Reference Value)

Sensitivity: ¥1,173–¥1,241 at Cost of Equity ±1%, and ¥1,203–¥1,208 at ω±0.1.

Notes:

• As forecast ROE is below the Cost of Equity, the theoretical value is below Book Value per Share.
• Net assets as of the end of the quarter are used (there is a timing difference from the full-year forecast).
• Because net assets include non-controlling interests, the theoretical value may be calculated somewhat higher.

(Calculation model: Residual Income Model (Ohlson-type, explicit 5-year fade) / Interest rate reference month: 2026-07 / This is a mechanically calculated value based solely on publicly disclosed data and is not a forecast of the market share price, a recommendation of any specific investment action, or a prediction or guarantee of future share prices.)

---

This report is an earnings analysis document automatically generated by AI based on XBRL earnings release data. It does not recommend investment in any specific security. The industry benchmarks are reference information compiled by our company based on publicly disclosed earnings data. Investment decisions should be made at your own discretion and responsibility, after consulting with professionals as necessary.

---End of Report---